Table 2 Comparison of clinocopathological features by gene mutations status compared with all-wild type in patients with AGC patients
All wild-type | KRAS codon 12/13 | PIK3CA exon 9/20 | NRAS codon12/13 | ||||
|---|---|---|---|---|---|---|---|
KRAS, BRAF, NRAS, PIK3CA | Mutant type | P-value | Mutant type | P–value | Mutant type | P-value | |
Number of patients | 70 | 8 | 9 | 3 | |||
Median age | 64.0 | 54.5 | 58.0 | 56.0 | |||
Gender (%) | |||||||
Male | 49 (70.0) | 7 (87.5) | 0.429 | 8 (88.9) | 0.432 | 2 (87.5) | 1.000 |
Female | 21 (30.0) | 1 (12.5) | 1 (11.1) | 1 (12.5) | |||
ECOG PS (%) | |||||||
0 | 38 (54.3) | 3 (37.5) | 0.466 | 4 (44.4) | 0.727 | 1 (33.3) | 0.476 |
1≦ | 32 (45.7) | 5 (62.5) | 5 (55.6) | 2 (66.7) | |||
Histological type (%) | |||||||
Intestinal type | 20 (28.6) | 6 (75.0) | 0.014 | 4 (44.4) | 0.443 | 0 (0.0) | 0.556 |
Diffuse type | 50 (71.4) | 2 (25.0) | 5 (55.6) | 3 (100.0) | |||
No. of metastatic site (%) | |||||||
1 | 54 (77.1) | 8 (100.0) | 0.195 | 8 (88.9) | 0.675 | 3 (100.0) | 1.000 |
2≦ | 16 (22.9) | 0 (0.0) | 1 (11.1) | 0 (0.0) | |||
Metastatic lesion (%) | |||||||
Lymph node | 41 (58.6) | 3 (37.5) | 0.348 | 6 (66.7) | 0.717 | 2 (66.7) | 0.851 |
Liver | 14 (20.0) | 3 (37.5) | 3 (33.3) | 1 (33.3) | |||
Lung | 2 (2.9) | 1 (12.5) | 0 (0.0) | 0 (0.0) | |||
Peritoneal dissemination | 18 (25.7) | 1 (12.5) | 1 (11.1) | 0 (0.0) | |||
Other | 3 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||